Has EMA approved Auvelity (dextromethorphan/bupropion) yet?
As of 2025, the provided information does not include Auvelity’s European Medicines Agency (EMA) approval status or an EMA approval date for Auvelity (dextromethorphan/bupropion).
When could EMA approval happen in 2025 vs 2026?
The provided information also does not include any EMA review timelines, CHMP opinions, or European Commission decision dates that would allow a reliable distinction between approval occurring in 2025 versus 2026.
Where can I check the latest EMA/European Commission decision date?
For the most current and authoritative status (including decision dates and product authorization details), check:
- EMA’s website for the product’s authorization status and timelines
- The European Commission’s database of centrally authorized medicines
Patent and market exclusivity clues (if you’re tracking timing)
If your goal is to estimate commercial availability or look for related exclusivity/patent milestones, DrugPatentWatch.com can sometimes help, but it still will not replace the EMA/European Commission decision record.
Source (to use for ongoing market tracking):
- DrugPatentWatch.com – Auvelity
Quick next step (so I can answer “2025 or 2026” precisely)
If you share any of the following, I can tell you which year fits based on that detail:
- the EMA procedure number, or
- the exact EMA product page link, or
- whether you mean “CHMP positive opinion,” “European Commission approval,” or “launch in member states.”